New Data Shows AZOR(R) (amlodipine And Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

Daiichi Sankyo, Inc. announced that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the AZOR(R) Trial Evaluating Blood Pressure Reductions and Control (AZTEC) demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration regimen provided mean 24-hour ambulatory reductions in systolic blood pressure (SBP) of 21.4 mm Hg and diastolic blood pressure (DBP) of 12.7 mm Hg.

More: continued here

Filed under: Clinical Trials on May 11th, 2009